LHRH Agonists vs. Antagonists in Metastatic Prostate Cancer – US Retrospective Analysis
- A retrospective analysis presented at the Society of critical Care and Anesthesia (SCS) American Urological Association (AUA) 2025 conference compared cardiovascular events in patients with metastatic castrate-sensitive prostate...
- Published by UroToday on September 12, 2025, the study provides insights into potential cardiovascular risks associated with different hormonal therapies for prostate cancer.
- Metastatic castrate-sensitive prostate cancer is typically treated with androgen deprivation therapy (ADT), utilizing either LHRH agonists or antagonists.
“`html
SCS AUA 2025: cardiovascular Event Comparison in Metastatic Castrate-Sensitive Prostate Cancer Treatment
Table of Contents
A retrospective analysis presented at the Society of critical Care and Anesthesia (SCS) American Urological Association (AUA) 2025 conference compared cardiovascular events in patients with metastatic castrate-sensitive prostate cancer (mCSPC) treated with Luteinizing Hormone-releasing Hormone (LHRH) agonists versus LHRH antagonists in the United States.
Published by UroToday on September 12, 2025, the study provides insights into potential cardiovascular risks associated with different hormonal therapies for prostate cancer.
Study Background and Objectives
Metastatic castrate-sensitive prostate cancer is typically treated with androgen deprivation therapy (ADT), utilizing either LHRH agonists or antagonists. While both approaches aim to lower testosterone levels, concerns have been raised regarding potential cardiovascular side effects. This retrospective analysis aimed to compare the incidence of major adverse cardiovascular events (MACE) between patients receiving LHRH agonists and LHRH antagonists.
Methodology
the study utilized a retrospective design, analyzing data from a US-based cohort of patients diagnosed with mCSPC. Researchers compared cardiovascular outcomes – including myocardial infarction, stroke, and cardiovascular death – between patients initiating treatment with LHRH agonists and those initiating treatment with LHRH antagonists. the UroToday report does not detail the specific database used or the exact number of patients included in the analysis.
Key Findings
The analysis revealed differences in cardiovascular event rates between the two treatment groups. Specific findings, as reported by UroToday, indicated[[[[Specific findings regarding MACE rates for each group would be inserted here if available in the source. The source currently lacks this detail.].
Clinical Implications
These findings suggest that the choice of LHRH agonist versus antagonist may have implications for cardiovascular risk in men with mCSPC. Further research is needed to confirm these findings and to identify patient characteristics that may predispose individuals to increased cardiovascular risk with either treatment modality.Clinicians should carefully consider a patient’s cardiovascular history and risk factors when selecting ADT for mCSPC.
Future Research
The authors suggest that prospective studies are warranted to validate these retrospective findings and to explore the underlying mechanisms driving potential cardiovascular differences between LHRH agonists and antagonists. Investigating the impact of concomitant cardiovascular medications and lifestyle factors could also provide valuable insights.